Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Booth

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Cancer Biology & Therapy|December 10, 2013
Not all antibodies are equalLaurence Booth
Immunometabolism|December 31, 2019
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory ImmunotherapiesPaul Dent, Laurence Booth, Andrew Poklepovic
Aging|July 19, 2016
Repurposing Tecfidera for cancerLaurence Booth, Mark Malkin, Paul Dent
Biochemical Pharmacology|June 7, 2020
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancerLaurence Booth, Andrew Poklepovic, Paul Dent
Expert Opinion on Therapeutic Targets|November 12, 2019
Not the comfy chair! Cancer drugs that act against multiple active sitesLaurence Booth, Andrew Poklepovic, Paul Dent
Oncotarget|December 17, 2017
Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen speciesJane L Roberts, Andrew Poklepovic, Laurence Booth
DNA and Cell Biology|February 18, 2015
HSPA5/Dna K may be a useful target for human disease therapiesLaurence Booth, Jane L Roberts, Paul Dent
Cancer Biology & Therapy|July 20, 2018
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cellsLaurence Booth, Jane Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 17, 2017
[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 25, 2018
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibodyLaurence Booth, Jane Lisa Roberts, Andrew Poklepovic, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|December 10, 2013
Not all antibodies are equalLaurence Booth
Immunometabolism|December 31, 2019
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory ImmunotherapiesPaul Dent, Laurence Booth, Andrew Poklepovic
Aging|July 19, 2016
Repurposing Tecfidera for cancerLaurence Booth, Mark Malkin, Paul Dent
Biochemical Pharmacology|June 7, 2020
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancerLaurence Booth, Andrew Poklepovic, Paul Dent
Expert Opinion on Therapeutic Targets|November 12, 2019
Not the comfy chair! Cancer drugs that act against multiple active sitesLaurence Booth, Andrew Poklepovic, Paul Dent
Oncotarget|December 17, 2017
Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen speciesJane L Roberts, Andrew Poklepovic, Laurence Booth
DNA and Cell Biology|February 18, 2015
HSPA5/Dna K may be a useful target for human disease therapiesLaurence Booth, Jane L Roberts, Paul Dent
Cancer Biology & Therapy|July 20, 2018
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cellsLaurence Booth, Jane Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 17, 2017
[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 25, 2018
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibodyLaurence Booth, Jane Lisa Roberts, Andrew Poklepovic, et al.
Pageof 10